Patent Application
20100099196
The present invention relates to a process for normalizing the concentration of analytes in a urine sample.
Urine samples have been used for medical laboratory examinations for a long time. Urine samples contain a variety of substances that are interesting under medical aspects, for example, degradation products of medicaments or illegal drugs, hormones, pathogens, proteins etc.
While often (only) the total protein content was recurred to for evaluating a urine sample in the past, it is recognized more and more that the composition of the proteins in urine, in particular, also contains relevant medical information.
WO 01/84140 and WO 2004/068130 describe Processes and devices for determining protein and peptide patterns in a liquid sample, for example, a urine sample.
WO 2005/024409 describes devices and processes for the quantitative evaluation of the polypeptides contained in a sample of body fluids and markers for recognizing pathological conditions. For example, it is shown how different diseases are associated with the occurrence of different polypeptide markers. It is observed that different polypeptides occur more or less frequently in certain diseases as compared to healthy patients.
WO 2006/106129 among others describes so-called amplitude markers in which two states, for example states of health and disease, are distinguished from one another, not by the occurrence, but by the amplitude, i.e., the concentration, of the markers in the sample. In order to compensate for different protein concentrations of different samples, the overall amplitude is normalized to 1 million counts after an examination of the sample by mass spectrometry in WO 2006/106129.
However, there is still a need for more specific normalization procedures for comparing different concentrations of analytes in the sample and therefore achieve a better comparability between the reference samples and measured samples.
Surprisingly, this object can be achieved by a process for normalizing the concentration of at least one analyte in a urine sample, comprising the following steps:
The process according to the invention has a wide variety of applications.
First, the content of analytes, collagen or collagen fragments is determined. For the determination, for example, UV/Vis detectors, fluorescence detectors, refractive index detectors, diode array detectors, mass spectrometers, gel scanners, the staining of the proteins, for example, with Coomassie brilliant blue, silver staining, Cy2, Cy3, Cy5 or the like, or the derivatization, for example, with ITRAC (isotope tags for relative and absolute qualification) and ICAT (isotope coded affinity tagging) followed by detection of the derivatized peptides may be used.
According to the invention, collagen or collagen fragments are employed for normalizing the samples. At least one collagen or collagen fragment is identified in the sample. For this purpose, identification by migration and retention times, in particular, optionally completed by mass spectra, UV/Vis spectra, fluorescence spectra or the affinity for particular ligands, for example, specific antibodies, is suitable.
The concentration of the analyte can then be normalized to the concentration of said at least one collagen or collagen fragment, i.e., the concentrations of analytes are measured relative to the concentration of the reference collagen or collagen fragments.
Preferably, however, not one collagen or collagen fragment, but several, for example, two or three or four or five or 10, 20, 30, 40 or 50 collagens or collagen fragments are employed for normalization.
In a preferred embodiment, the analyte does not comprise any hydroxypyridinium collagen cross-links, especially no hydroxylysylpyridinoline (Pyd) and deoxypyridinoline (Dpd). Preferably, none of these compounds is employed for normalizing the concentration of another analyte either.
Preferably used collagen fragments are stated in the following Table:
The sequences are given in
The invention also relates to the use of collagen fragments for normalizing the analyte concentration of urine samples, especially with the collagen fragments as described above.
Preferred analytes whose contents are to be normalized include, in particular, proteins, peptides, lipids, metabolites, salts and other ionic compounds, carbohydrates.
The use of the process for normalizing peptide concentrations is particularly preferred.
In one embodiment, the sample is first subdivided into subsamples.
Different methods may be employed to achieve this, for example:
The invention is further illustrated by the following Examples:
A urine sample was examined by means of HPLC with a downstream diode array detector (DAD). The raw date are stated in the Table. Peaks were identified by means of the retention time and spectra in the DAD. The measurement was compared with previously determined standards for these four collagen fragments, and a conversion factor was calculated for each. The average of these factors (0.80761277 in this case) was employed as a normalizing factor for all the other signals. The normalized signals are stated in the last column.
A urine sample was separated by means of 2D electrophoresis as described in Thongboonkerd et al. in Kidney Int 62: 1461-1469 (2002), over a pH range of from 3 to 10 and using a 10% polyacrylamide gel having a length of 22 cm. The gel was stained with Coomassie stain, and the collagens were detected in a gel prepared in parallel by means of immunological methods (Western blot). Predetermined standards for these five proteins were employed, and a linear regression performed. With this calibration formula, the further values were converted. The formula was Y=103.82x−127449. The R2 value was 0.957.
The quality of the regression is shown in
A urine sample was examined by capillary electrophoresis coupled with mass spectrometry. Twenty-seven collagen fragments could be identified thereby, which were then compared with previously determined standards. This was followed by normalization by means of linear regression with the proviso that the straight line must go through the value zero. Corresponding measuring data and the calibration are shown in the following Table.
The quality of the regression is shown in
| Number | Date | Country | Kind |
|---|---|---|---|
| 07103684.2 | Mar 2007 | EP | regional |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP2008/052730 | 3/6/2008 | WO | 00 | 1/4/2010 |
